Editorial summary of secondary reporting. Not medical advice. Regulatory history is contested; readers should verify primary sources and consult clinicians before use.

From breakthrough buzz to blackout

The Vigilant Fox article opens with a blunt comparison: if you followed the fights over ivermectin, look at DMSO. In the 1960s and 1970s, doctors, athletes, and even politicians pushed for access to a compound said to ease chronic pain, speed soft-tissue healing, and calm inflammatory flares. Thousands of biology papers and tens of thousands of chemistry papers accumulated. Then, the Fox narrative argues, the FDA’s restrictions—and the fact that a cheap, unpatentable solvent threatened lucrative pain franchises—pushed DMSO out of mainstream U.S. practice.

The profit-and-patent angle

Because DMSO is easy to manufacture from paper-industry streams, it is hard to monopolize the way a novel molecule can be. The piece claims that dynamic made it a structural threat to NSAIDs and other chronic pain drugs that patients often take indefinitely. Whether one accepts a full “regulatory capture” story or prefers a narrower reading (messy safety signals, sprawling indications, post-thalidomide caution), the outcome is similar: most Americans, even in natural-health circles, barely know the name.

What the safety section stresses

• No clear cumulative toxicity in ordinary use patterns described
• Cell-protective behavior in many stress models rather than routine cytotoxicity
• Animal tolerance at very high doses; extreme human overdose thresholds cited as far above typical use
• Millions of historical exposures with mostly minor complaints

Common effects: transient skin itch or burn when applied strong and undiluted; garlic-like breath or body odor from metabolism; occasional nausea. Serious allergy is described as roughly 1 in 1,000–2,000. Cancer and birth-defect scares are addressed by distinguishing ordinary exposure from extreme lab injections into embryos. The practical hazard the authors emphasize is misuse as a carrier: whatever is on the skin can ride inward, so cleanliness and product quality matter.

Evidence vs. official messaging

The Fox essay contrasts an alleged FDA posture of “no evidence it works” with Midwestern Doctor’s catalogs of studies and patient stories—bruises resolving quickly, nerve pain easing, arthritis flares calming, even cataract anecdotes. Those testimonials are persuasive to communities that already distrust institutions; scientifically, they remain hypotheses until replicated in rigorous modern trials. DMSO’s continued niche approvals (notably interstitial cystitis) and laboratory ubiquity complicate any claim that medicine “rejected” the molecule entirely.

Why the story keeps returning

Like the companion Vigilant Fox history piece, this installment treats DMSO as both a possible therapy and a civics lesson: when people believe useful options are hidden, unofficial networks fill the gap. Sharing primary research, demanding transparent risk–benefit analysis, and avoiding miracle marketing are all compatible responses. If DMSO re-enters wider practice, it will likely do so through careful protocols, standardized purity, and honest acknowledgment of what is proven versus what is hoped.

Source

Original article: The FDA’s 50-Year War on the Safest Painkiller Ever Discovered — The Vigilant Fox (Jul. 2, 2025), based on reporting by A Midwestern Doctor.